Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + famitinib + temozolomide for advanced clear cell sarcoma
ChiCTR2400085510Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, famitinib and temozolomide in clear cell sarcoma (CCS), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Progression-free survival rate at 6 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
camrelizumabfamitinibtemozolomide
03
Conditions
clear cell sarcoma (CCS)
Beyond the preview
Go deeper on ChiCTR2400085510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085510.